Helicore Biopharma

Facts

as of Nov 17, 2026

Long-Acting Medicines to Transform Metabolic Health. Pioneering long-acting antibody conjugates to deliver quarterly administered, best-in-category therapies for obesity and cardiometabolic disease.

Legal name
Helicore, LLC
Headquarters
Southbury, United States
Founded
2020
Employees
1-10estimated range
Register numbers
NAME helicore llc
Official records
SEC CIK 1810144
Website
helicore.com

These are the key facts about Helicore Biopharma on Alion as of Nov 17, 2026. Helicore Biopharma is headquartered in Southbury, United States. It was founded in 2020. The latest round is Venture - Series Unknown of $2M, announced in 2020.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Helicore, LLC
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
SiteTypeOpen rolesHires most forEngineering
Southbury United StatesHeadquarters0
Source: office addresses in postings and company registers

Financials

Funding rounds, investors and revenue on record.

$2MTotal raised
Venture - Series UnknownLatest round
1Rounds and grants
Money by yearUSD, rounds and grants
2020$2M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers

Milestones

Each milestone is dated by its source: registers, filings, the press

Newsroom

Jan 28, 20252025
News · YahooFinance
HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half of 2025 Building on existing validation of GIP pathwa…
Jan 27, 20252025
News · bioworld.com
Helicore Biopharma Inc. has emerged from stealth with $65 million in series A financing and a focus on first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists f…
Sources: the outlets named on each headline, each story once